Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.22 -1.6%	$4.68	$1.00 ▼ $7.00	$46.25M	0.67	228,849 shs	16,765 shs
DTIL Precision BioSciences	$4.49 +2.4%	$4.71	$3.61 ▼ $11.09	$52.88M	1.52	336,974 shs	105,379 shs
KLTO Klotho Neurosciences	$0.77 -4.1%	$1.19	$0.11 ▼ $3.91	$35.66M	10.9	18.01 million shs	937,042 shs
LPTX Leap Therapeutics	$0.34 +6.1%	$0.34	$0.22 ▼ $4.79	$14.21M	-0.27	1.68 million shs	376,237 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-0.38%	-1.85%	+15.47%	+29.27%	+324.00%
DTIL Precision BioSciences	+0.69%	-9.88%	-1.57%	-11.52%	-50.45%
KLTO Klotho Neurosciences	-2.97%	-17.62%	-37.90%	+179.15%	+80,729,900.00%
LPTX Leap Therapeutics	+3.62%	-1.70%	-1.97%	-20.93%	-86.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.5198 of 5 stars	3.3	3.0	0.0	0.0	3.8	1.7	0.0
DTIL Precision BioSciences	4.212 of 5 stars	3.5	3.0	0.0	4.6	2.1	1.7	0.6
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	2.5165 of 5 stars	3.0	4.0	0.0	0.0	2.7	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	130.11% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	947.94% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
LPTX Leap Therapeutics	2.00	Hold	$3.38	883.97% Upside

Current Analyst Ratings Breakdown

Latest LPTX, DTIL, ATHE, and KLTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
DTIL Precision BioSciences	$68.70M	0.77	N/A	N/A	$2.89 per share	1.55
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	N/A
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	8/18/2025 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.70	N/A	N/A	N/A	N/A	-162.15%	-120.05%	N/A

Latest LPTX, DTIL, ATHE, and KLTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
DTIL Precision BioSciences	0.66	5.18	5.18
KLTO Klotho Neurosciences	N/A	0.29	0.29
LPTX Leap Therapeutics	N/A	2.41	2.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
DTIL Precision BioSciences	37.99%
KLTO Klotho Neurosciences	20.07%
LPTX Leap Therapeutics	30.46%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
DTIL Precision BioSciences	4.00%
KLTO Klotho Neurosciences	26.70%
LPTX Leap Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
DTIL Precision BioSciences	200	11.79 million	11.32 million	No Data
KLTO Klotho Neurosciences	N/A	46.05 million	33.76 million	N/A
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable

LPTX, DTIL, ATHE, and KLTO Headlines

Recent News About These Companies

Leap Therapeutics (LPTX) Expected to Announce Earnings on Monday

August 10 at 2:59 AM | americanbankingnews.com

Leap Therapeutics, Inc. (LPTX) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Leap Therapeutics Initiates Process To Explore Strategic Options

June 24, 2025 | nasdaq.com

Leap Slashes 75% of Workforce, Explores Strategic Options

June 24, 2025 | biospace.comB

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

June 23, 2025 | prnewswire.com

Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025 | finanznachrichten.de

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'

May 13, 2025 | fiercebiotech.comF

Leap Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025 | prnewswire.com

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

April 25, 2025 | prnewswire.com

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

April 15, 2025 | prnewswire.com

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

March 31, 2025 | seekingalpha.com

H.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)

March 27, 2025 | markets.businessinsider.com

Leap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

March 26, 2025 | finanznachrichten.de

Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025 | finanznachrichten.de

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025 | prnewswire.com

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

March 26, 2025 | prnewswire.com

Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

January 29, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)

January 29, 2025 | msn.com

Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral

January 29, 2025 | msn.com

Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%

January 29, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LPTX, DTIL, ATHE, and KLTO Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.22 -0.09 (-1.60%)

As of 02:26 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Precision BioSciences NASDAQ:DTIL

$4.49 +0.11 (+2.40%)

As of 02:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Klotho Neurosciences NASDAQ:KLTO

$0.77 -0.03 (-4.08%)

As of 02:10 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Leap Therapeutics NASDAQ:LPTX

$0.34 +0.02 (+6.06%)

As of 02:28 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time